UPB · Upstream Bio, Inc. · Executive Compensation
$4.85
-0.19 (-3.77%)
At close · Oct 5
Return incl. dividend (before tax)
Going-concern doubt
— cleared May 13, 2026
The latest filing states the doubt was alleviated.
“The Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within one year from the issuance of these condensed consolidated financial statements. The Company expects its cash, cash equivalents and short-term investments will be sufficient to fund its operating expenses and capital expenditure requirements for at least the next twelve months from the date of issuance of these condensed consolidated financial statements.”View the 10-Q filed May 13, 2026
Market Cap
$293.57M
Shares
54.77M
Volume · Oct 5
1.01M
Avg daily vol (3M)
598.16K
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| E. Rand Sutherland | Chief Executive Officer | $4,302,100 |
| Michael Paul Gray | M.B.A. Chief Financial Officer and Chief Operating Officer | $1,993,437 |
| Aaron Deykin | Chief Medical Officer and Head of Research and Development | $1,830,916 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| E. Rand Sutherland | Chief Executive Officer | $9,108,953 |
| Michael Paul Gray | M.B.A. Chief Financial Officer and Chief Operating Officer | $2,938,577 |
| Allison Ambrose | Sr. Vice President, General Counsel | $1,533,837 |
| Samantha Truex | Former Chief Executive Officer | $872,507 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Samantha Truex | Former Chief Executive Officer | $1,663,252 |